Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121172 | 0.89 | GAA (0.50) | GAACCR1KDM4EPOLBTSHR | |
| SCHEMBL1879572 | 0.88 | GAA (0.48) | GAACCR1KDM4EPOLBTSHR | |
| SCHEMBL2509441 | 0.88 | GAA (0.50) | GAACCR1KDM4EPOLBTSHR | |
| SCHEMBL2593635 | 0.87 | POLB (0.44) | GAACCR1KDM4EPOLBTSHR | |
| SCHEMBL1879570 | 0.87 | GAA (0.49) | GAACCR1KDM4EPOLBTSHR | |
| SCHEMBL8512452 | 0.87 | GAA (0.49) | GAACCR1KDM4EPOLBTSHR | |
| SCHEMBL2580001 | 0.87 | GAA (0.49) | GAACCR1KDM4EPOLBTSHR | |
| SCHEMBL20727027 | 0.86 | POLB (0.44) | GAACCR1KDM4EPOLBTSHR | |
| SCHEMBL12186082 | 0.86 | GAA (0.48) | GAACCR1KDM4EPOLBTSHR | |
| SCHEMBL1227053 | 0.86 | GAA (0.44) | GAACCR1KDM4EPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722678-B2 | Fungicidal oximes and hydrazones | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2571866-A1 | FUNGICIDAL OXIMES AND HYDRAZONES | E.I. Du Pont De Nemours And Company (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130030002-A1 | FUNGICIDAL OXIMES AND HYDRAZONES | E I DUPONT DE NEMOURS AND COMPANY (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2011146182-A1 | FUNGICIDAL OXIMES AND HYDRAZONES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030002-A1 | FUNGICIDAL OXIMES AND HYDRAZONES | NOX1, QSOX1, XDH | GAA 329/4885CCR1 1632/4885KDM4E 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.